Literature DB >> 20451283

A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System.

Chia-Yang Hsu1, Yi-Hsiang Huang, Cheng-Yuan Hsia, Chien-Wei Su, Han-Chieh Lin, Che-Chuan Loong, Yi-You Chiou, Jen-Huey Chiang, Pui-Ching Lee, Teh-Ia Huo, Shou-Dong Lee.   

Abstract

BACKGROUND & AIMS: The currently used staging systems for hepatocellular carcinoma (HCC) are not satisfactory. The optimal prognostic model for HCC is still under intense debate. This study aimed to propose a new staging system for HCC based on total tumor volume (TTV) and to compare it with the currently used systems.
METHODS: A total of 2030 HCC patients undergoing different treatment strategies were retrospectively analyzed. TTV was defined as the sum of the volume of each tumor [(4/3)x3.14x(radius of tumor in cm)(3)]. The discriminatory ability of the TTV-based staging system and the four current systems, including the Barcelona Clinic Liver Cancer, Cancer of the Liver Italian Program (CLIP), Japan Integrated Staging system, and Tokyo system, was examined by comparing the Akaike information criterion (AIC) using the Cox proportional hazards model.
RESULTS: A higher TTV correlated well with the decreased survival in HCC patients (p<0.001). Among the 12 TTV-based staging systems, the TTV-Child-Turcotte-Pugh (CTP)-alpha-fetoprotein (AFP) combination provided the lowest AIC value. The TTV-CTP-AFP model consistently showed a better prognostic ability in comparison to the current four staging systems. In 936 HCC patients receiving curative treatment, the TTV-CTP-AFP model provided the second best predictive accuracy following the CLIP score. Alternatively, in 1094 patients undergoing non-curative treatment, the TTV-CTP-AFP model exhibited the smallest AIC value.
CONCLUSIONS: TTV may be a feasible tumoral prognostic predictor for HCC. In this single-hospital study that included patients with early to advanced cancer stages, the TTV-CTP-AFP model provides the best prognostic ability among 12 TTV-based and currently used staging systems. Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20451283     DOI: 10.1016/j.jhep.2010.01.038

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  55 in total

Review 1.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  When to consider liver transplantation in hepatocellular carcinoma patients?

Authors:  Ka Wing Ma; Tan To Cheung
Journal:  Hepat Oncol       Date:  2017-07-06

3.  Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience.

Authors:  Wei-Fan Hsu; Po-Heng Chuang; Cheng-Kuo Chen; Hung-Wei Wang; Ming-Hung Tsai; Wen-Pang Su; Hung-Yao Chen; Chi-Ying Yang; Chun-Che Lin; Guan-Tarn Huang; Jaw-Town Lin; Hsueh-Chou Lai; Cheng-Yuan Peng
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

4.  A Novel Score Predicts HBV-Related Hepatocellular Carcinoma Recurrence After Hepatectomy: a Retrospective Multicenter Study.

Authors:  Wei Qin; Li Wang; Beiyuan Hu; Shusheng Leng; Huan Tian; Huanxian Luo; Jia Yao; Xiaolong Chen; Chao Wu; Guihua Chen; Yang Yang
Journal:  J Gastrointest Surg       Date:  2018-11-16       Impact factor: 3.452

5.  Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma.

Authors:  Gia L Tyson; Zhigang Duan; Jennifer R Kramer; Jessica A Davila; Peter A Richardson; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2011-08-04       Impact factor: 11.382

6.  Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Ya-Ju Tsai; Chia-Yang Hsu; Yi-Hsiang Huang; Chien-Wei Su; Han-Chieh Lin; Rheun-Chuan Lee; Jen-Huey Chiang; Teh-Ia Huo; Shou-Dong Lee
Journal:  Hepatol Int       Date:  2011-04-30       Impact factor: 6.047

Review 7.  Treatment of intermediate-stage hepatocellular carcinoma.

Authors:  Alejandro Forner; Marine Gilabert; Jordi Bruix; Jean-Luc Raoul
Journal:  Nat Rev Clin Oncol       Date:  2014-08-05       Impact factor: 66.675

8.  Prognostic Factors and Clinical Characteristics for Hepatocellular Carcinoma Patients with Benign Enlarged Perihepatic Lymph Nodes: a Single-Center Experience from China.

Authors:  Fei Tian; Jian-Xiong Wu; Wei-Bo Yu
Journal:  J Gastrointest Surg       Date:  2015-08-11       Impact factor: 3.452

9.  Surgical resection is better than transarterial chemoembolization for hepatocellular carcinoma beyond Milan criteria independent of performance status.

Authors:  Po-Hong Liu; Yun-Hsuan Lee; Chia-Yang Hsu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Yi-You Chiou; Han-Chieh Lin; Teh-Ia Huo
Journal:  J Gastrointest Surg       Date:  2014-05-29       Impact factor: 3.452

10.  Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival.

Authors:  Marco Biolato; Luca Miele; Vittoria Vero; Simona Racco; Carmine Di Stasi; Roberto Iezzi; Andrea Zanché; Maurizio Pompili; Gian Ludovico Rapaccini; Giuseppe La Torre; Antonio Gasbarrini; Antonio Grieco
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.